Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: A physical training system for pelvic floor muscle, wherein the physical training system for pelvic floor muscle is capable of providing at least one optional exercising setting to user for making the physical training system for pelvic floor muscle can guide the user to accomplish at least one exercising movement, wherein the exercising setting is selected from a group of exercising settings, wherein the group of exercising settings comprises an exercising movement setting, an exercising time setting, an exercising intensity setting, an exercising frequency setting, an exercising guidance setting, an exercising auxiliary setting and an exercising feedback setting, wherein the physical training system for pelvic floor muscle comprises a processor and a Client, wherein the processor is capable of providing at least one optional exercising setting to user, wherein the exercising settings are set to be displayed on the Client.

Abstract: An image sensing apparatus including a light source, an image sensor, at least one lens, and a wavelength selecting device is provided. The light source is configured to emit an illumination light to irradiate an object. The image sensor is configured to receive a light signal from the object and send an image signal corresponding to the light signal. The at least one lens is located on a transmission path of the light signal and between the object and the image sensor. The wavelength selecting device is located on the transmission path of the light signal and between the object and the image sensor. The wavelength selecting device has a first reflector and a second reflector, and a gap exists between the first reflector and the second reflector. The gap is adapted to be adjusted to have a first predetermined optical path length or a second predetermined optical path length.

Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: A clock data recovery (CDR) circuit includes: a band select circuit, a low dropout regulator (LDO), a charge pump and a voltage-controlled oscillator (VCO), wherein the band select circuit is arranged to generate a digital signal according to at least a reference voltage; the LDO is arranged to regulate a ground voltage, wherein the LDO adjusts an operating band of the LDO by receiving at least a part of the digital signal to adjust a bias current of an amplifier of the LDO; the charge pump is arranged to generate a control voltage according to at least a part of the digital signal; and the VCO is arranged to generate a clock signal according to the control voltage, wherein the VCO adjusts an operating band of the CDR circuit by receiving at least a part of the digital signal to adjust a bias current of the VCO.

Abstract: A clock data recovery (CDR) circuit includes: a band select circuit, a low dropout regulator (LDO), a charge pump and a voltage-controlled oscillator (VCO), wherein the band select circuit is arranged to generate a digital signal according to at least a reference voltage; the LDO is arranged to regulate a ground voltage, wherein the LDO adjusts an operating band of the LDO by receiving at least a part of the digital signal to adjust a bias current of an amplifier of the LDO; the charge pump is arranged to generate a control voltage according to at least a part of the digital signal; and the VCO is arranged to generate a clock signal according to the control voltage, wherein the VCO adjusts an operating band of the CDR circuit by receiving at least a part of the digital signal to adjust a bias current of the VCO.

Abstract: Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: Disclosed is a residual toxicant detection device for detecting the amount of residual toxicants in an aqueous solution to be measured. The residual toxicant detection device includes an accommodation space formed from a shell, a water inlet and a water outlet positioned on the shell for the aqueous solution to flow therein and thereout, respectively, a sensing chamber in the accommodation space, a light source emitter and a light sensor positioned near the sensing chamber, the light source emitter emitting light of a wavelength range, the light sensor receiving the light passing through the sensing chamber, and a circuit board receiving sensing signals sensed by the light sensor, such that absorbance and a change of the absorbance of residual toxicants in the aqueous solution to be measured are calculated.

Abstract: Provided is a residual toxicant detection system and a residual toxicant detection method, the residual toxicant detection method including: allowing an aqueous solution containing a residual toxicant to flow into a detection portion including a cavity; providing at a side of the cavity a light containing a specific wavelength range to react with the residual toxicant; receiving the light that passes through the cavity on another side of the cavity, thereby generating a sensing signal; and calculating an amount of change in absorbance of the aqueous solution according to the sensing signal, wherein when the amount of change in absorbance is less than a threshold value, a detection count is accumulated, and when the accumulated detection count is greater than a predetermined value, a detection result is generated. Therefore, whether or not the residual toxicant on the object is cleaned can be determined easily and accurately.

Abstract: A display device framework and a display device, solving technical problem of application limitation of existing display device frameworks due to an integral structure thereof. The display device includes: a rear frame (20) configured to support at least a display panel (21); and a front frame (10) configured to support at least an out-cell panel (11), wherein, the front frame (10) and the rear frame (20) are flexibly connected so as to be movable with respective to each other along a first direction (101), wherein the first direction is perpendicular to a display panel (21) upon the display panel (21) being supported. The display device includes at least the display device framework.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: A backlight unit (10) and a display device are provided. The backlight unit (10) comprises a light guide plate (101), and a light source (102), a first reflective film (101), and a second reflective film (104). The light source (102) includes a plurality of LEDs (1021) uniformly arranged. The first reflective film (103) is disposed correspondingly on a backlight side of a region opposite to each of the LEDs on the light guide plate (101); The second reflective film (104) includes at least one first sub-reflective film (1041), the first sub-reflective film (1041) being disposed correspondingly on a backlight side of a region opposite to a gap between two adjacent LEDs on the light guide plate (101).

Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: An optical package is provided. The optical package includes an interference splitter allowing a light having a predetermined wavelength range to transmit through, a sensing element, and a light-transmitting structure. The light-transmitting structure includes a light-transmitting pillar and a light-absorbing layer surrounding the light-transmitting pillar, and the light-absorbing layer absorbs the light having the predetermined wavelength range. The interference splitter, the light-transmitting pillar, and the sensing element are arranged aligned with each other along an extending direction of the light-transmitting pillar. The sensing element is configured to receive the light transmitting through the interference splitter and the light-transmitting pillar.

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: An automatic slicing and collecting device, the device including: a first tank, a vibrating microtome, a first pipeline, and a second pipeline. The first tank is filled with a buffer solution. The vibrating microtome is disposed in the first tank. One end of the first pipeline is connected to the vibrating microtome to collect sections, and the other end of the first pipeline is connected to a pump. The pump includes a reversible motor. The first pipeline is provided with a first valve, and a filter is disposed between the pump and the first pipeline. One end of the second pipeline is disposed between the first valve of the first pipeline and the pump, and the second pipeline is provided with a second valve.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.